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Available online 17 July 2015Background: Prospective data on chemotherapy for (frail) elderly patients with advanced
colorectal cancer (aCRC) are scant. UFT/leucovorin might be as effective as and less toxic
than capecitabine. We firstly randomized both agents in patients >65 years with aCRC not
amenable to receive combination chemotherapy.
Patients and Methods: Patients were randomised between first-line oral UFT/leucovorin and
capecitabine in a Dutch multicentre trial. Primarily, efficacy and toxicity were determined.
Secondary, quality of life (QoL) and abbreviated common geriatric assessment (aCGA) were
analysed.
Results: Sixty-seven patients were randomised with a median age of 77 years and 96% being
frail. After interim analysis it was decided to stop recruitment because of low accrual. At a
median followup of 34 months, themedian progression-free survival (PFS) andoverall survival
(OS) were similar for both therapies, being 21 weeks (p = 0.17) and 12 months (p = 0.83),
respectively. The overall response rates were 24% and 21%, respectively. Two patients died
of possible treatment related complications in the UFT/leucovorin arm and 3 patients
in the capecitabine arm. For UFT/leucovorin significantly less grade 3 or 4 hand/foot
syndrome (0 vs 5) was observed. Overall, PFS was related to Charlson-comorbidity index
(p = 0.049), LDH (p = 0.0011) and albumin (p = 0.009). OS was related to LDH (p = 0.0003),Keywords:
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Advanced colorectal cancer
Chemotherapy
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308 J O U R N A L O F G E R I A T R I C O N C O L O G Y 6 ( 2 0 1 5 ) 3 0 7 – 3 1 5albumin (p = 0.0001), QoLC30/CR38 (p = 0.041), QoL visual analogue scale (VAS; p = 0.016),
and GFI (p = 0.028).
Conclusion: UFT/leucovorin and capecitabine had similar efficacy and different toxicity
profiles in frail elderly patients with aCRC. Baseline serum levels of albumin and LDH,
Charlson-comorbidity index, GFI and QoL were prognostic for clinical outcome.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
About 70% of patients with colon cancer are >65 years of age and
the number of elderly patients is increasing, both due to an
increase in life expectancy and the increasing population.1
Despite this growing colorectal cancer burden in elderly patients
themajority of studies exploring the optimal strategy in patients
with advanced colorectal cancer (aCRC) is based on studies in
patients that are considerably younger. Elderly patients more
often have co-morbidity and for them combination chemother-
apy can be associated with greater toxicity and less overall
benefit.2 Currently, themost common first line chemotherapy for
treatment of patients with aCRC unsuitable to receive combina-
tion chemotherapy or mono-chemotherapy with bevacizumab,
is monotherapy with a fluoropyrimidine. Both 5-fluorouracil
prodrugsUFT, tegafur plus uracil that inhibits dihydropyrimidine
dehydrogenase the rate-limiting enzyme in 5-fluorouracil catab-
olism, and capecitabine have already shown good tolerability
and efficacy in the elderly.3,4 However, these agents have never
been compared in a randomised study.Wehypothesised that the
different patterns of toxicity may result in a preferable drug for
this population. In addition, this study would add to the limited
prospective data onelderly patientswith aCRCs treatedwith first
line systemic palliative chemotherapy. We therefore initiated
this randomised trial comparing UFT and capecitabine in elderly
patients with aCRC not suitable for or not willing to receive
combination chemotherapy. In order to bettermonitor the study
population we measured, in addition to efficacy and toxicity of
the two oral treatments, serum levels of albumin and LDH,
quality of life (QoL) and an abbreviated comprehensive geriatric
assessment (aCGA).
1.1. Study Population
Patients were eligible for inclusion if they were at least
65 years of age, had histologically proven aCRC, measurable
disease, not amenable to treatment with curative intent and
not amenable or willing to receive combination chemother-
apy or mono-chemotherapy with bevacizumab. Patients also
had to have a WHO performance score 0–2, a life expectancy
of >3 months, and adequate bone marrow, liver and renal
function. Frailty was defined as having two or more comor-
bidities according to the Charlson co-morbidity index and/or
a Gronigen frailty indicator (GFI) score >4. Patients were
excluded from the study if they had received prior chemo-
therapy for aCRC (prior adjuvant chemotherapy was allowed
provided that the last administration was given > 6 months
prior to randomisation), known or suspected central nervous
system metastasis, another malignancy in the previous
5 years (with exception of a history of previous basal cell
carcinoma of the skin or pre-invasive carcinoma of thecervix), chronic diarrhoea or inflammatory bowel disease,
known as dihydropyrimidine dehydrogenase (DPD) deficiency,
clinically relevant coronary artery disease, a high risk of
uncontrolled arrhythmia, or history of myocardial infarction
in the last 12 months or a medical or psychological condition
which, in the opinion of the investigator, would not permit the
patient to complete the study or sign meaningful informed
consent. The study was approved by the Ethics Committees of
the Leiden University Medical Center and all local participating
institutions. Written informed consent was obtained from all
patients.
1.2. Treatment and Evaluation
After randomisation patients received UFT/leucovorin (UFT
150 mg/m2 orally, b.i.d, plus leucovorin 30 mg, b.i.d., days 1–28,
Q5 weeks) or capecitabine (1250 mg/m2, b.i.d, days 1–14, Q3
weeks) until disease progression or unacceptable toxicity in the
TLC study (NTR1268, Dutch trial register, www.trialregister.nl).
Toxicity was graded according to the common toxicity
criteria for adverse events (CTCAE), version 3.0. Patients
were assessed clinically at least every 5 weeks and response
evaluation was carried out every 9 weeks during therapy and
at the end of study treatment, using RECIST criteria version
1.0. Questionnaires on QoL, using the EORTC QoL Question-
naire C-30, CR38 and visual analogue scale (VAS), and an
aCGA were completed at study entry. The surveys were
planned to be administered prior to randomization, and
thereafter every 9 weeks with a final survey at the end of
treatment. The aCGA examined the co-morbidity (Charlson
co-morbidity index, cut-off score >2),5 instrumental activities
of daily life (IADL; cut-offs for partial dependence 14–27,
full functional dependence <13),6 geriatric depression scale
(GDS; cut-off for severe depressive symptoms >10, moderate
depressive symptoms 5–9),7 and Groningen Frailty Index
(GFI; cut-off of 4 or more for frailty).8 Subgroup analyses of
PFS and OS were performed for baseline patients character-
istics (WHO performance score and age), baseline serum
levels of LDH <400 vs >400 and albumin <35 vs >35, QOL
and aCGA.
1.3. Statistical Methods
The primary end point of the studywas progression free survival
(PFS), defined as the duration from the time of randomisation
until first observation of radiologically confirmed progressive
disease or death due to any cause, whichever occurred first.
Secondary endpoints included overall survival (OS) defined as
the duration from the time of randomisation until death from
any cause, objective response rate, toxicity and the evaluation of
QoL and aCGA.
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progression, it was considered that only differences in the
median PFS of >6 weeks (HR = 1.4 UFT/capecitabine) were
medically relevant. With 277 events, the upper limit of the
confidence interval of the hazard ratio would not exceed 1.4
with 80% power and a sample size of 300 patients.
Randomisation was stratified by WHO performance status
(0–1 vs. 2), age (65–69, 70–79, and >80 years) and prior adjuvant
therapy (with fluoropyrimidine vs. without a fluoropyrimidine
vs. any prior adjuvant therapy). If the difference in PFS was
not medically relevant, the choice of treatment would be
based on other considerations: better QoL or less toxicity.
All end points were analysed according to the intention-
to-treat principle, except toxicity which included only pa-
tients who received at least one therapy dose. The analyses
of PFS and OS by treatment were based on the stratified
log-rank test. The Kaplan–Meier method was used to esti-
mate PFS and OS curves and hazard ratios were calculated
using Cox proportional hazards models. Two sided p-values
are presented.Fig. 1 – CONSORT diagram of the study.2. Results
2.1. Conduct of the Trial
Between January 8, 2008 and July 30, 2012, 15 participating
Dutch hospitals enrolled a total of 67 patients. An interim
analysis on grade 3/4 adverse events was done in December
2011 after inclusion of 46 patients. This test, with 1-sided
significance level 0.05 and 90% power for the hypothesis of
40% grade 3/4 adverse events in the capecitabine and 20%
in the UFT arm, showed that the futility boundary was
not crossed. The study was closed prematurely in July 2012
due to slow accrual, partly because of the introduction of
bevacizumab for treatment of first line aCRC. This limited
the sample size to 67. The cut-off date for analysis was
January 29, 2014, resulting in a median follow up of 34 months.
All patients were eligible for efficacy analysis and 66 for toxicity
analysis.
2.2. Patient Characteristics
Fig. 1 depicts the CONSORT diagram of the study. Patient
characteristics are shown in Table 1. The median age was
77 years. Most patients (94%) were >70 years. The median
Charlson co-morbidity index was 1 with a range from 0–10.
The majority of patients (96%) were frail, defined as having
two or more comorbidities, with 22% and 33% of the patients
in the UFT and capecitabine arm, respectively and/or a GFI 4–9
score in 94% of patients.
2.3. Survival and Response Rate
Sixty-five of the 67 patients had a PFS event, 33 in the UFT/
leucovorin group and 32 in the capecitabine group. The median
PFS was 20 weeks (95% confidence interval (CI) 19.5–27.6) in
the UFT/leucovorin group and 23 weeks (95% CI 13.4–40.4) in
the capecitabine group, hazard ratio (HR) 0.66 (95% CI 0.37–1.19,
p = 0.17, Fig. 2a).No significant difference in overall survival (OS) was ob-
served between the chemotherapy regimens (Fig. 3). Median OS
was 12 months (95% CI 8–16 months) for UFT/leucovorin and
13 months (95% CI 5–17 months) for capecitabine (HR 0.94;95%
CI 0.52–1.70; p = 0.83).
The best overall response rate percentages were 24% (all
partial responses) for UFT/leucovorin and for capecitabine
21% (2 complete responses and 5 partial responses, Table 2).
2.4. Baseline Quality of Life and Comprehensive Geriatric
Assessment
Baseline QLQ-C30 and -CR38 questionnaires were available from
60/67 and 52/67 patients respectively. Baseline co-morbidity was
known from55/67 patients. Baseline IADL, GDS, GFI and VASwas
known from 54, 54, 51 and 39 out of 67 patients, respectively. All
missing questionnaires were well-balanced between the arms.
Subgroup analyses for PFS were performed for all patients
combined as well as compared between the 2 chemotherapy
regimens. For all patients combined, PFSwas significantly higher
for those without co-morbidity as compared to those with a
Charlson comorbidity index >2 (Fig. 2b; log rank test p = 0.049).
PFS was almost statistically significantly different for Charlson
comorbidity index with optional age extension (p = 0.07) and for
age (p = 0.10), and not different for QoL (p = 0.57), IADL (p = 0.45),
GDS (p = 0.14), VAS (p = 0.64) and GFI (p = 0.82).PFS was signifi-
cantly related to serum LDH (p=0.0011) and albumin (p=0.009)
(Fig.4).
OS was significantly related to baseline WHO performance
score (p = 0.042), serumLDH (p = 0.0011) and albumin (p = 0.009),
QoL (p = 0.041), VAS (p = 0.016) and GFI (p = 0.028).
The subgroup analyses for all these variables in terms of
PFS and OS showed no difference between the 2 chemother-
apy regimens.
Fig. 2 – a: Progression free survival UFT/lV vs capecitabine
(stratified logrank test p = 0.17). b: Progression free survival
by Charlson index (logrank test p = 0.049).
Table 1 – Patient characteristics.
Patients UFT/
leucovorin
Capecitabine Total
34 33 67
Age
Median (range) 77 (66–88) 76 (66–88) 77 (66–88)
65–69 2 (6%) 2 (6%) 4 (6%)
70–79 19 (56%) 19 (58%) 38 (57%)
80–88 13 (38%) 12 (36%) 25 (37%)
Gender
Male 19 (56%) 17 (52%) 36 (54%)
Female 15 (44%) 16 (48%) 31 (46%)
WHO performance
status
0 10 (30%) 6 (20%) 16 (25%)
1 20 (61%) 19 (63%) 39 (62%)
2 3 (9%) 5 (17%) 8 (13%)
NA 1 3 4
Charlson co-morbidity
index
Median (range) 1 (0–10) 1 (0–7) 1 (0–10)
Frailty (Charlson
and/or GFI)
CCI > 2 or GFI > 4 24 (92%) 27 (100%) 51 (96%)
CCI 0–1 and GFI < 3 2 (8%) 0 (0%) 2 (4%)
NA 8 6 14
Disease stage
IIIA 0 (0%) 0 (0%) 0 (0%)
IIIB 1 (3%) 2 (7%) 3 (5%)
IIIC 0 (0%) 1 (3%) 1 (2%)
IV 30 (97%) 27 (90%) 57 (93%)
NA 3 3 6
Site of primary tumour
Colon 19 (56%) 19 (59%) 37 (57%)
Rectum 13 (39%) 12 (38%) 25 (38%)
Both 1 (3%) 0 (0%) 1 (2%)
Prior adjuvant therapy
With a
fluoropyrimidine
3 (9%) 3 (9%) 6 (9%)
Without a
fluoropyrimidine
1 (3%) 0 (0%) 1 (1%)
No prior adjuvant
therapy
30 (88%) 30 (91%) 60 (90%)
CCI = Charlson comorbidity index; GFI = Groningen frailty indicator;
NA = not available.
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The safety population consisted of 66 patients in the randomised
population who received any dose of study drug (one patient in
the capecitabine arm, who did not start therapy, was excluded).
Adverse events of CTC grade 3 or higher were considered. During
treatment, there were 56 > grade 3 adverse events, 28 events in
both arms (Table 3). Two patients died of possibly treatment
related complications in the UFT/leucovorin arm (pulmonary
embolus and unknown reason) and 3 in the capecitabine arm
(1 dyspnoea and 2 ischemic CVA). Only 2 patients developed
grade >3 hematologic toxicity. Five patients, all in the UFT/
leucovorin group received erythropoietin and only one patient in
the capecitabine arm had a grade 3 anaemia. For UFT/leucovorin
there seemed to be more grade 3/4 diarrhoea (9 vs 4 patients,
although not statistically significant p = 0.22), but there wassignificantly less grade 3/4 hand/foot syndrome (0 vs 5 patients,
p = 0.023).
Adverse events >grade 3 were not related to baseline
co-morbidity, quality of life or one of the other aCGAs.
2.6. Treatment Duration
A median of 4 cycles of chemotherapy were administered for
both UFT/leucovorin and capecitabine with a range of 1–8 and
0–21, respectively. A dose reduction was applied for UFT/
leucovorin in 15/34 (44%) patients after a median of 43 days
and for capecitabine in 15/33 (47%) after a median of 44 days.
Reasons for permanent treatment cessation for UFT/leucovorin
and capecitabine were toxicity (15 vs 33%), progressive disease
(65 vs 39%), patient refusal (both 9%), death (both 6%) and other
reasons (6%: investigator decision that included the patients
Fig. 3 – a: Overall survival UFT/LVvs capecitabine (stratified logrank test p = 0.83). b: Overall survival byQol (logrank test p = 0.041).
c: Overall survival by VAS (logrank test p = 0.016). d: Overall survival by GFI (logrank test p = 0.028).
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according to exclusion criteria, investigator decision because of
the patients condition, CVA, liver surgery, delayed restart of
chemotherapy).3. Discussion
In this multicenter randomised phase III study in elderly
patients with aCRC, for the first time, two oral 5-fluorouracil
analogues were compared; tegafur–uracil/leucovorin and cape-
citabine. Efficacy defined by response rate, PFS and OS was
similar for both agents. However, as this study was closed
prematurely owing to poor accrual itmayhave failed tomeet itsprimary end point of showing a difference in PFS between the
two arms. Therefore, data in these elderly patients on toxicity,
QoL, and geriatric indexes and on toxicities between the
regimens was of more importance.
Sequential treatment, startingwith first-line fluoropyrimidine
monotherapy, is a valid alternative, for advanced colorectal
cancer, to combination chemotherapy in the majority of
patients with metastatic colorectal cancer.9 In elderly patients
the toxicity profile of mono-chemotherapy with both UFT/
leucovorin or capecitabine seems to be favourable as compared
to combination chemotherapy and 5-fluorouracil monotherapy.10
In a recent phase III trial comparing first line capecitabine plus
bevacizumab with capecitabine alone in elderly patients with
aCRC, PFS was significantly longer with bevacizumab plus
Table 2 – The best overall response and reasons for
non-evaluability.
Randomized treatment
UFT Capecitabine Total
Patients 34 33 67
Best overall response
Complete response 0 (0%) 2 (6%) 2 (3%)
Partial response 8 (24%) 5 (15%) 13 (19%)
Stable disease 11 (32%) 11 (33%) 22 (33%)
Progressive disease 6 (18%) 7 (21%) 13 (19%)
Not evaluable 9 (26%) 8 (24%) 17 (25%)
Reasons for non-evaluability
Not finished enough
cycles to evaluate
response (<3 cycles)
9 6 14
Never started therapy 0 1 1
Clinical PD (not measured) 0 1 1
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9·1 months vs 5·1 months (hazard ratio 0·53, p < 0·0001) while
OS was not significantly different.11 Treatment-related adverse
events of grade 3 or worse occurred twice as much in the
combination group; with hand–foot syndrome being most
common (16% vs 7%). In our trial chemotherapy was feasible,
even in the frail patients. In the UFT/leucovorin arm
numerically more grade 3/4 diarrhoea was observed, while
there was significantly more grade 3/4 hand–foot syndrome
in the capecitabine arm. For both UFT/leucovorin and
capecitabine a lower incidence of leucopenia, stomatitis/
mucositis and less fever and infection have been reported
compared to 5FU/leucovorin.12–15 However, as compared to
5FU/leucovorin, capecitabine displayed a higher incidence of
hand–foot syndrome. Especially in frail elderly patients the
trade-off between benefits and side effects, even possible
mortality, should be discussed and shared decision making
implemented.16 The evidence obtained in this trial might help
in this discussion.
Uniquely, this trial recruited a high proportion of frail
patients, not amenable to combination chemotherapy or mono-
chemotherapy with bevacizumab. There are various outcome
measurements to measure frailty.17 Using the Charlson co-
morbidity index and the Groningen frailty index 96% of our
patients were characterized as being frail. Frailty is one of the
greatest challenges for healthcare professionals. Frail older
adults are at high risk for major adverse health outcomes,
including disability, toxicity, falls, institutionalization, hospitali-
zation, and mortality.
Although themajority of patients in the trial was frail elderly,
efficacy results with a median OS of 12 months are comparable
to earlier trials with less frail patients. In Phase III trials that
compared both agents separately with 5-fluorouracil/leucovorin,
an OS of 12 months for UFT/leucovorin12,13 and 13 months for
capecitabine14,18 were reported; phase II trials that made the
same comparison in 26 and 51 elderly (70+) patients with aCRC
showed an OS of 9.8 months and 11 months, respectively.3,4
CGA is helpful in identifying vulnerability in elderly
patients with cancer so that treatment can be adjusted
accordingly19,20 and predicts morbidity and mortality in
older patients with cancer.21 However, this process is time-
consuming and the exact roles of the aCGA or a frailtyscreening tool in decision-making regarding treatment remain
to be clarified.22 The optimal balance between feasibility and
predictive value remains to be determined.
Interestingly, in this study both baseline serum albumin
and LDH were related to PFS and OS. PFS was significantly
higher for patients with one comorbidity or less as compared
to those with more than one comorbidity, while Qol scores
and GFI scores were predictive for OS. The data on serum
albumin are in accordance with our earlier data that malnutri-
tion was strongly associatedwith an increasedmortality risk in
patients with aCRC who underwent palliative chemotherapy.23
Instead of a mini-nutritional assessment we only measured
baseline serum albumin in this study as a surrogate parameter
for nutritional status. Serum LDH level has previously been
defined as the main prognostic factor in predicting survival in
patients treated with first-line chemotherapy for aCRC.24 Also,
QOL, co-morbidity and GFI have been previously associated
with clinical outcome in elderly patients.21,25 To the best of our
knowledge, the use of VAS for QoL has not been related to
outcome in the elderly before. Importantly baseline LDH,
albumin andVASare relatively easy to obtain.With the growing
incidence of cancer in elderly patients, understanding of
chemotherapy sensitivity and toxicity with an emphasis on
patient selection by a reliable and efficient aCGA is becoming
essential.
Since February 2013 the trade licence for UFT expired in
Europe. In Japan, Taiwan, South Korea, Singapore andMalaysia,
UFT is still commercially available. The oral fluoropyrimidine,
S-1, might become the successor of UFT. S-1 consists of tegafur
combined with two biochemical fluorouracil modulators. It has
shown good efficacy combined with oxaliplatin, has a similarly
favourable toxicity profile toUFT and is currently being tested in
phase III trials.27
Our trial has some limitations. Firstly the study was closed
prematurely due to slow accrual, partly because of the registra-
tion of bevacizumab for treatment of first line aCRC, which
resulted in the inclusion of mostly frail patients not suitable
for or not willing to receive combination chemotherapy or
mono-chemotherapy with bevacizumab. Frail patients are less
amenable to receive chemotherapy and frail patients often start
with chemotherapyat a lower dose. However, nowwehavedata
on the usage of chemotherapy in a unique population of frail
patients. During treatment, a dose reduction was necessary in
almost half of the patients.
Secondly, the patients in our study underwent an
aCGA after the medical oncologist decided that they were
eligible to receive chemotherapy, which may have intro-
duced some selection bias. Furthermore, we did not screen
parameters like nutritional status and mini-mental state
examination (MMSE). However, we could therefore mini-
mise the burden of testing which resulted in good compli-
ance (>80%).
In conclusion, this is one of the few randomised studies in
frail elderly patients with aCRC. It shows that UFT/leucovorin
and capecitabine had similar efficacy and dissimilar toxicity
profiles in favour of UFT. In this frail population we identified
QoL using VAS as a new prognosticator for clinical outcome
and were able to confirm that baseline serum levels of LDH
and albumin, Charlson co-morbidity index, Qol and GFI were
predictors for clinical outcome.
Fig. 4 – a: Progression free survival by albumin (logrank test p = 0.009). b: Progression free survival by LDH (logrank test p = 0.0011).
c: Overall survival by albumin (logrank test p = 0.0001). d: Overall survival by LDH (logrank test p = 0.0003).
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